Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
|Articles|April 24, 2012
Services Match Patients With Clinical Trials
Advertisement
A growing number of patient-advocacy groups are playing matchmaker, linking patients to researchers who need them for clinical trials.
The move comes as a persistent shortage of volunteers has slowed trials of new treatments for cancer and other diseases, which typically involve a patient receiving a drug or a placebo. People, including healthy volunteers, also are urgently needed for studies to contribute to the overall understanding of diseases including Parkinson's and Alzheimer's, experts say.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
5